McKinsey January 9, 2023
Neha Patel and Shubham Singhal

Recent developments have complicated the outlook for industry profit pools.

When we last looked at the trajectory of the US healthcare industry in our July 2022 article, “The future of US healthcare: What’s next for the industry post-COVID-19?,” we had emerging concerns about what persistent inflation could cause.1 It is now clear that inflation is not transitory and that the economic outlook has meaningfully darkened.2 These economic troubles, combined with a healthcare-worker shortage and endemic COVID-19, are clouding the industry outlook. Below, we update how these changes could affect payers, providers, healthcare services and technology (HST), and pharmacy services.

Commercial and Medicare Advantage segments, physician offices, HST and specialty pharmacy segments may grow most quickly.

Based on updated...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Employer, Govt Agencies, Healthcare System, Insurance, Medical Devices, Patient / Consumer, Payment Models, Pharma, Pharma / Biotech, Provider
The Ripple Effect: Ways to Make Health in All Policies Stick in Kansas and Beyond to Enhance Health and Equity
Katie Couric Talks Colon Cancer, Health Equity And AI
Ernst & Young: Health equity efforts maturing, but data capabilities remain barrier
Research Funding Is Needed To Support An Effective, Equitable, And Sustainable Public Health System
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time

Share This Article